Amendment of the Non-Exclusive Patent License



 Exhibit 4.30 
  

	*	CONFIDENTIAL INFORMATION HAS BEEN OMITTED AND FILED SEPARATELY WITH THE SECURITIES AND EXCHANGE COMMISSION. REDACTED PORTIONS OF THIS EXHIBIT ARE MARKED BY AN *.


  
 PUBLIC HEALTH SERVICE 
  
 AMENDMENT L-007-96/1 
  
 This Amendment of the Non-Exclusive Patent License, L-007-96/0
(“Agreement”), L-007-96/1 (“Amendment”), is made between the National Institutes of Health (“NIH”), the Centers for Disease Control and Prevention (“CDC”), or the Food and Drug
Administration (“FDA”), hereinafter singly or collectively referred to as (“PHS”), agencies of the United States Public Health Service within the Department of Health and Human Services (“DHHS”)
through the Office of Technology Transfer, NIH, having an address at 6011 Executive Boulevard, Suite 325, Rockville, Maryland 20852-3804, U.S.A., and Amersham Health Inc. (“Licensee”), having an office at 101 Carnegie Center,
Princeton, New Jersey 08540). 
  
 Whereas, Licensee desires the
Agreement to be amended, a first time, in order to clarify the meaning of Section 2 of Appendix C of the Agreement; and 
  
 Whereas, PHS is willing to amend the Agreement a first time in order to facilitate this clarification. 
  
 Now Therefore, PHS and Licensee, intending to be bound, hereby agree that the
following change will be made to the Agreement: 
  

	1.	New Paragraph 2(a) for Appendix C will be added: 

  
 For clarification, PHS agrees that the * royalty, due under this Agreement, shall be applied to and based upon the net sales of the product
as described and defined in the related exclusive patent license L-006-96/0 (‘006 agreement). PHS further agrees that this * royalty shall not be applied to any component of the drug delivery system, as defined by the Licensed Patent
Rights, required to deliver the product as described and defined in the ‘006 agreement. Additionally and for example, while the ‘006 agreement and this Agreement are in effect, Licensee shall pay the PHS a minimum
of * of net sales of the product as described and defined in the ‘006 agreement, specifically, * under the ‘006 agreement and an additional * under this Agreement. Licensee agrees that the total earned royalties due to the
PHS can rise to a total of * should the provisions of the related exclusive patent license, L-287-00/0 (‘287 agreement) be in effect. In this case, * under the ‘006 agreement, * under this Agreement and * under the ‘287
agreement. 
  

	2.	All terms and conditions of the Agreement not herein amended remain binding and in effect; 

  

	3.	The Agreement and this Amendment constitute the entire understanding between PHS and Licensee and supersede all prior Agreements and understandings with
respect to the Licensed Product(s) and/or Licensed Process(es); and 

  

 Page 1 of 2 









	4.	This Amendment is effective when signed by all parties. 

  
 SIGNATURES BEGIN ON NEXT PAGE 
  

 Page 2 of 2 








 AMENDMENT TO PHS LICENSE AGREEMENT L-007-96/0 
 SIGNATURE PAGE 
  
 In Witness Whereof, the parties have executed this agreement on the dates set forth below. Any communication or notice to be given shall be forwarded to the respective addresses listed below. 
  

					
	 For PHS:
	 	 	 	 
			
	 /s/ Jack Spiegel
	 	 	 	 7/17/2002

	 Jack Spiegel, Ph.D
	 	 	 	 Date

	 Director, Division for Technology Development and
	 	 	 	 
	 Transfer
	 	 	 	 
	 National Institutes of Health
	 	 	 	 

  
 Mailing Address for Notices:

  
 National Institutes of Health 
 Office of Technology Transfer 
 6011 Executive
Boulevard, Suite 325 
 Rockville, MD 20852 
  
 For Licensee (The undersigned expressly certifies or affirms that the contents of any statements of Licensee made or referred to in this document are
truthful and accurate.) 
  

					
			
	 /s/ Ase Aulie Michelet
	 	 	 	 5/8/2002

	 Signature of Authorized Official
	 	 	 	 Date

			
	 Ase Aulie Michelet
	 	 	 	  
	 Printed Name
	 	 	 	 
			
	 President
	 	 	 	  
	 Title
	 	 	 	 

  
 Official and Mailing Address for
Notices: 
  

			
	 AMERSHAM HEALTH AS
	  	 U.S. Contact:

	 Nycoveien 2
	  	 AMERSHAM HEALTH INC.

	 Post Office Box 4220
	  	 101 Carnegie Center

	 Torshov, B0401
	  	 Princeton, New Jersey 08540

	 Oslo, Norway
	  	 

  

 Page 3 of 2